Latest on Anabolic Agents for Osteoporosis Treatment

被引：2
|
作者：
di Filippo, Luigi [1 ,2 ]
Rosen, Clifford J. [3 ]
机构：
[1] Univ Vita Salute San Raffaele, Inst Endocrine & Metab Sci, Milan, Italy
[2] IRCCS Osped San Raffaele, Milan, Italy
[3] Main Ehlth Inst Res, Ctr Clin & Translat Res, Scarborough, ME 04074 USA
来源：
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA | 2024年 / 53卷 / 04期
关键词：
Osteoporosis; Anabolics; Teriparatide; Abaloparatide; Romosozumab; Blosozumab; Fragility fractures; Glucocorticoids; PARATHYROID-HORMONE; 1-34; BONE-MINERAL DENSITY; POSTMENOPAUSAL WOMEN; DOUBLE-BLIND; ABALOPARATIDE; TERIPARATIDE; ROMOSOZUMAB; FRACTURE; RISK; PLACEBO;
D O I：
10.1016/j.ecl.2024.08.003
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The efficacies of anabolic compounds in preventing fragility fractures and increasing BMD were progressively and widely demonstrated in the last decades. Latest updated clinical data (Table 1) in this setting have markedly downgrading their potential serious side effects including risk of malignancies in teriparatide- and cardiovascular events in romosozumab-users, respectively. Further future data are warranted about their potential efficacy in patients with GIO and, interestingly, their use is currently investigated also in fracture healings setting.
引用
收藏
页码：513 / 523
页数：11
相关论文
共 50 条
  • [21] Anabolic agents: what is beyond osteoporosis?
    Y. Liu
    A. E. Levack
    E. Marty
    O. Or
    B. P. Samuels
    M. Redko
    J. M. Lane
    Osteoporosis International, 2018, 29 : 1009 - 1022
  • [22] Anabolic Therapies for Osteoporosis
    Uihlein, Alexander V.
    Leder, Benjamin Z.
    ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2012, 41 (03) : 507 - +
  • [23] Molecular understanding of pharmacological treatment of osteoporosis
    Tanaka, Sakae
    EFORT OPEN REVIEWS, 2019, 4 (04): : 158 - 164
  • [24] Current Treatment of Osteoporosis
    Nallasivan, Subramanian
    INDIAN JOURNAL OF RHEUMATOLOGY, 2019, 14 (01) : 57 - 60
  • [25] Medical treatment of osteoporosis
    Palacios, S.
    CLIMACTERIC, 2022, 25 (01) : 43 - 49
  • [26] 2020 recommendations for osteoporosis treatment according to fracture risk from the Swiss Association against Osteoporosis (SVGO)
    Serge, Ferrari
    Kurt, Lippuner
    Olivier, Lamy
    Christian, Meier
    SWISS MEDICAL WEEKLY, 2020, 150 : w20352
  • [27] Romosozumab: a novel bone anabolic treatment option for osteoporosis?
    Kerschan-Schindl, Katharina
    WIENER MEDIZINISCHE WOCHENSCHRIFT, 2020, 170 (5-6) : 124 - 131
  • [28] Treatment Sequence Matters: Anabolic and Antiresorptive Therapy for Osteoporosis
    Cosman, Felicia
    Nieves, Jeri W.
    Dempster, David W.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2017, 32 (02) : 198 - 202
  • [29] Anabolic treatment for osteoporosis and fragility fracture risk: one year in review 2024
    De Mattia, G.
    Maffi, M.
    Mazzantini, M.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2024, 42 (07) : 1311 - 1316
  • [30] The Role of Novel Bone Forming Agents in the Treatment of Osteoporosis
    Patel, Hansita B.
    Lyerly, Lynsie J.
    Horlen, Cheryl K.
    JOURNAL OF PHARMACY PRACTICE, 2021, 34 (06) : 952 - 961
12345